安徽地区绝经后妇女雌激素受体基因多态性与骨密度的相关性研究

目的探讨安徽地区绝经后妇女雌激素受体（ER）基因多态性的分布及其与骨密度的相关性。方法随机选择288名安徽合肥地区健康绝经后妇女，运用双能X线骨密度吸收法（DEXA）测定腰椎和股骨颈、大转子骨密度（BMD），并采用PCR-RFLP（聚合酶链反应-限制性片断长度多态性）法分析ER基因多态性，并分析其相关性。结果安徽地区绝经后妇女ER基因型分布频率PP（13．2％）、Pp（45．8％）、pp（40．9％），XX（5．21％）、Xx（31．6％）、xx（63．2％），联合PvuⅡ和XbaⅠ这两种基因型后得到：PPXX（5．6％），PPXx（3．8％），PPxx（6．3％），PpXX（1．4％），PpXx（23．3％），Ppxx（25％），ppxx（34．7％），未检测到ppXX及ppXx型。PvuⅡ多态性与绝经后妇女腰椎BMD相关，PP基因型腰椎BMD显著低于pp和Pp基因型（P〈0．05），ER基因P等位基因是一种有益于骨量的基因型。XbaⅠ多态性与绝经后妇女各部位BMD间无明显相关性（P〉0．05）。联合分析PvuⅡ和XbaⅠ多态性与绝经后妇女BMD相关性发现，有Px单倍型的妇女腰椎部位的BMD显著低于无此单倍型的妇女（P〈0．01）。结论ER基因PVuⅡ多态性与绝经后妇女腰椎BMD有相关性，PP基因型妇女腰椎BMD减低，而具有Px单倍型的ER基因可能对BMD有不利影响。     

Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy

Osteoporosis is a major public health concern. The combination of exercise, hormone replacement therapy, and calcium supplementation may have added benefits for improving bone mineral density compared to a single intervention. To test this notion, 320 healthy, non-smoking postmenopausal women, who did or did not use hormone replacement therapy (HRT), were randomized within groups to exercise or no exercise and followed for 12 months. All women received 800 mg calcium citrate supplements daily. Women who exercised performed supervised aerobic, weight-bearing and weight-lifting exercise, three times per week in community-based exercise facilities. Regional bone mineral density (BMD) was assessed by dual energy X-ray absorptiometry. Women who used HRT, calcium, and exercised increased femoral neck, trochanteric and lumbar spine bone mineral density by approximately 1–2%. Trochanteric BMD was also significantly increased by ~1.0% in women who exercised and used calcium without HRT compared to a negligible change in women who used HRT and did not exercise. The results demonstrate that regional BMD can be improved with aerobic, weight-bearing activity combined with weight lifting at clinically relevant sites in postmenopausal women. The response was significant at more sites in women who used HRT, suggesting a greater benefit with hormone replacement and exercise compared to HRT alone.     

绝经妇女骨密度变化与雌激素、生长激素水平的相关关系初探

收集61饲病例，分为生育年龄组13例，绝经前组10例，绝经后组38例，均进行血碱性磷酸酶(ALP)、血钙(Ca)、血磷(P)、雌二醇(E2)、促卵泡素(FSH)、生长激素(GH)及空腹尿钙／尿肌酐(尿Ca／Cr)测定，其中3组进行定量CT测定腰椎骨密度(BMD)，分别为13、7、28例；其中绝经后组中10侧患者服用尼尔雌醇(CEE3)3个月：结果显示绝经后妇女BMD显著下降，其BMD与E2及GH呈正相关．在绝经早期组中BMD与尿Ca／Cr值呈负相关．诨步回归分析显示绝经年限对绝经后妇女BMD影响最大，其次为GH；服CEE3 3个月后血ALP显著下降，尿Ca／Cr显著下降，GH升高。本文提示GH的下降是绝经后骨代谢变化的膨响因素之：CEE，能有效防止绝经后妇女的骨丢失，但长期应用有待进一步的研究。     

绝经后妇女骨质疏松性椎体骨折与腰椎骨密度的关系

目的探讨绝经后妇女骨质疏松性椎体骨折与腰椎骨密度的关系。方法选择骨质疏松性椎体骨折的绝经后妇女23例为骨折组,无椎体骨折的25例绝经后骨质疏松妇女为对照组。两组的年龄、绝经年限、身高、体重、体重指数差异无显著性,均行胸腰椎正侧位X线摄片。用双能X线吸收仪（DXA）测量的腰椎（L2-4）前后位骨密度（BMD）、骨矿含量（BMC）和T值。结果骨折组BMD、BMC和T值均低于对照组（P〈0.01）。结论腰椎BMD降低与绝经后妇女的骨质疏松性椎体骨折相关。绝经后骨质疏松妇女应重视BMD变化,预防椎体骨折的发生。     

利塞膦酸钠干预绝经后妇女骨量的研究(附223例报告）

目的评价口服利塞膦酸钠对绝经后妇女骨量变化的干预作用。方法223名绝经后妇女随机分为两组:A组(利塞膦酸钠,5mg/d,口服)和B组(安慰剂,每天1片),所有患者每天补充钙剂500mg和维生素D200IU,治疗1年。腰椎和髋部(包括股骨颈、转子间和Ward三角)骨量双能X骨密度测量分别于治疗前、治疗6个月和12个月时进行。结果所有患者为骨量减少,治疗前患者的一般情况和骨量两组间无差异。治疗结束后,利塞膦酸钠组患者腰椎和股骨颈的骨量较安慰剂对照组明显上升(P<0.05)。结论口服利塞膦酸钠可显著提高腰椎和髋部骨量,有效防治绝经后骨质疏松。     

大豆异黄酮对绝经后妇女骨的影响

目的 从临床角度研究大豆异黄酮对兰州地区绝经后妇女骨的影响。方法 在兰州地区筛选出绝经后妇女60人,随机分为大豆异黄酮组(SIF)和对照组(Control),每人每天服用大豆异黄酮90mg或者同等剂量安慰剂,时间6个月。抽血检测血清碱性磷酸酶和血清钙、磷,超声测定胫骨中段骨密度（BMD）。 结果 血清碱性磷酸酶显著下降（P<0.05）,血清钙显著升高（P<0.05）,胫骨中段BMD显著升高（P<0.05）。结论 大豆异黄酮可增加绝经后妇女骨密度,减少骨丢失。因而可以预防治疗骨质疏松症。     

绝经后女性握力与骨密度的相关性研究

目的研究绝经后女性握力和骨密度的相关性。方法对120例绝经后女性进行握力测量和骨密度测定,观察≤60岁组、61~70岁组和70岁组的握力和骨密度变化,应用单因素Person相关性分析和散点图研究握力与骨密度的相关性。结果最大握力:≤60岁组25.86±4.77 kg,61~70岁组23.37±4.64 kg,70岁组16.63±5.40 kg。骨密度测定提示:65例股骨颈T值≤-2.5;90例腰椎T值≤-2.5。最大握力与骨密度均随年龄增加而减少。握力与股骨颈和腰椎骨密度呈非常显著正相关。结论绝经后女性握力越大,股骨颈和腰椎骨密度越高。     

Comparison of the effects of transdermal estrogen, oral estrogen, and oral estrogen-progestogen therapy on bone mineral density in postmenopausal women

It is now clear that estrogen intervention reduces bone loss in postmenopausal osteoporosis. The aim of this study was to investigate whether the route of estrogen administration or addition of progesterone changes this positive effect. Transdermal estrogen (T-E), oral estrogen (E), and oral estrogen plus progestogen (E-P) were administered to 15, 18, and 17 postmenopausal women, respectively, who all had normal bone mineral density (BMD) before hormone replacement therapy (HRT). Calcium (500 mg/day) was routinely added to all HRT regimens. The BMD of the lumbar spine (L2–L4) was measured initially and at the end of the first and second years of treatment. The paired-sample t test, independent-sample t test, and Pearson correlation analysis were used for the statistical evaluation. The initial BMD measurements and the values at the end of the first and second years of the therapy were not significantly different either within or among the groups (P > 0.05). These results indicate a similar therapeutic value of each HRT regimen in the prevention of bone loss in postmenopausal women. Received: May 1, 2001 / Accepted: August 22, 2001     

绝经后妇女血脂水平与骨密度的关系

目的 明确绝经后妇女血脂水平与骨密度有否联系。方法 测定85例绝经后妇女的甘油三酯和胆固醇水平，双能X线法测定腰椎k2-4和股骨颈的骨密度(BMD)。结果 与未绝经妇女相比，绝经后妇女甘油三酯(t=3．74，P=0．000)和胆固醇(t=3．75，P=0．000)水平均显著升高；而BMD腰椎k(t=2．43，P=0．017)和股骨颈(t=3．32，P=0．002)均显著降低；绝经后妇女甘油三酯水平与股骨颈的BMD经BMI校正后有显著负相关，偏相关系数r=-0．324，P=0．003；而与腰椎k2-4 BMD无相关。胆固醇水平则与股骨颈及腰椎k2-4的BMD均无相关性。结论 绝经后妇女甘油三酯水平的升高可能是绝经后骨量减少及骨质疏松发生的因素之一。     

喝牛奶与绝经后妇女骨密度关系的临床研究

目的 探讨喝牛奶与绝经后妇女骨密度的相关性。方法 随机选择1478例福州汉族绝经后妇女,喝牛奶组795例,不喝牛奶组683例,双能X线骨密度仪测定腰椎、股骨颈、大转子和Ward区骨密度,SPSS 18.0统计软件分析喝牛奶与不同部位骨密度的关系。结果 ①喝牛奶组与不喝牛奶组两组比较,结果为年龄、体重、质量指数有差异。②腰椎骨密度与年龄、体重指数、喝牛奶、体重进行逐步回归分析（y=0.843-0.003×年龄-0.010×BMI+0.006×体重+0.016×喝牛奶,β=0.392,回归系数t检验P=0.000）,体重对腰椎骨密度影响较大。③体重、体重指数、年龄为协变量,喝牛奶为变量,行协方差分析,喝牛奶组腰椎BMD（0.754±0.138g/cm2）明显高于不喝牛奶组（0.742±0.113g/cm2）,统计学有显著性差异(F=5.935,P=0.015),股骨颈骨密度无差异。④喝牛奶组骨质疏松患病率为69.18%,不喝牛奶组患病率为71.16%,两者比较无差异（P=0.42）。结论 喝牛奶可维持绝经后女性腰椎高骨密度,这类人群适量饮用牛奶,一定程度上,具有预防骨质疏松的作用。     

The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized,double-blind,placebo-controlled trial

We studied the effect of 1-year transdermal estrogen replacement therapy (ERT) on bone mineral density (BMD) and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus (SLE) patients in a randomized, double-blind, placebo-controlled trial. SLE patients were randomly allocated to treatment (estradiol; 50 g transdermal 17-estradiol; n=15) or placebo (n=17) group. Both groups received 5 mg continuous oral medroxyprogesterone acetate, 500 mg calcium and 400 IU vitamin D₃. L₁–L₄ spine (LS), left femur and total hip BMD were measured at baseline and at 6 and 12 months. Serum osteocalcin (OC) and degradation products of C-terminal telopeptides of type-I collagen (CTx) levels were measured at baseline and 3, 6, 9, and 12 months. There was a significant difference in the percentage change of LS BMD at 6 months between the two groups (103.24±3.74% (estradiol group) vs 98.99±3.11% (placebo group); P<0.005). There was a significant decrease within the estradiol group in the CTx levels between baseline and all subsequent visits (P<0.05). There was no significant difference in SLE disease activity index, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) damage index and corticosteroid dose during the study period. Transdermal estradiol may prevent bone loss in postmenopausal SLE women at the lumbar spine and femur, with no increase in disease activity among postmenopausal SLE women receiving transdermal ERT. The high dropout rate (8/15) leads us to the conclusion that efficacy of HRT in a high-risk group such as SLE women can be attained only in a small number of patients, provided all inclusion/exclusion criteria are strictly adhered to.     

绝经妇女绝经后年限及年龄与骨量丢失率关系

目的探讨绝经后妇女的绝经年限及年龄与骨量丢失率关系。方法1999年5月-2003年4月,对已绝经的1467例妇女进行骨密度测定,并对不同绝经后妇女年龄、绝经年限与骨密度关系进行分析。结果1467例绝经后妇女中,以绝经1-5年期间和40-45岁时各部位骨密度作为基线值比较,绝经已超过35年或年龄大于80岁时各部位骨密度最低。其中按绝经年限腰椎、股骨颈、大转子、华氏三角区在绝经后6-10年间和超过35年时丢失速度最快;按年龄腰椎在56-65岁、股骨颈和华氏三角区在61-65岁、大转子在71-75岁及各部位大于80岁时丢失速度最快。结论绝经后妇女绝经年限及年龄增加,腰椎、股骨颈、粗隆、华氏三角区骨量丢失增加。绝经年限及年龄不同,各部位丢失速度不同。     

辛伐他汀对绝经伴血脂代谢异常女性跟骨骨密度的影响

目的 研究辛伐他汀对绝经后伴血脂代谢异常女性跟骨骨密度的影响。方法 分析885名绝经后口服辛伐他汀治疗血脂代谢异常（TC>5.18mmol/L 或 LDL-C> 3.37mmol/L）女性的跟骨骨密度,并依据T值分为骨质正常、骨量减少、骨质疏松。结果 治疗前跟骨骨密度为305.3± 59.2 mg/cm2,骨质正常、骨量减少、骨质疏松的人数分别为115、446、324,口服辛伐他汀（20mg/d）治疗3月后骨密度为309.7±56.3 mg/cm2,骨质正常、骨量减少、骨质疏松的人数为117、459、319,12月后跟骨骨密度为312.5±60.9 mg/cm2,骨质正常、骨量减少、骨质疏松的人数为122、460、303。结论 绝经后伴血脂代谢异常女性应用辛伐他汀（20mg/d）治疗12个月后跟骨骨密度增高,但对骨质疏松患病风险无影响。     

Physical training preserves bone mineral density in postmenopausal women with forearm fractures and low bone mineral density

Summary One hundred and twelve postmenopausal women with low bone mineral density (BMD) and forearm fractures were randomized to physical training or control group. After one year the total hip BMD was significantly higher in the women in the physical training group. The results indicate a positive effect of physical training on BMD in postmenopausal women with low BMD. Introduction The fivefold increase in hip fracture incidence since 1950 in Sweden may partially be due to an increasingly sedentary lifestyle. Our hypothesis was that physical training can prevent bone loss in postmenopausal women. Methods One hundred and twelve postmenopausal women 45 to 65 years with forearm fractures and T-scores from −1.0 to −3.0 were randomized to either a physical training or control group. Training included three fast 30-minute walks and two sessions of one-hour training per week. Bone mineral density (BMD) was measured in the hip and the lumbar spine at baseline and after one year. Results A per protocol analysis was performed, including 48 subjects in the training group and 44 subjects in the control group. The total hip BMD increased in the training group +0.005 g/cm2 (±0.018), +0.58%, while it decreased −0.003 g/cm2 (±0.019), −0.36%, (p = 0.041) in the control group. No significant effects of physical training were seen in the lumbar spine. A sensitivity intention to treat analysis, including all randomized subjects, showed no significant effect of physical training on BMD at any site. Conclusions The results indicate a small but positive effect of physical exercise on hip BMD in postmenopausal women with low BMD.     

绝经后骨质疏松人群雌激素受体基因Xba I多态性和年龄对骨密度的影响

目的 分析绝经后骨质疏松人群雌激素受体(ER)基因XbaⅠ多态性与骨密度的相关性以及在基因多态性下年龄、绝经年限及体重指数(BMI)对骨密度的影响。方法 用双能X线骨密度仪检测患者151例，以PCR-RFLP的方法检测ER基因XbaⅠ多态性，SPSS软件进行相关回归分析。结果 ER基因型的频率分布为XX型16．6％，Xx型67．5％，xx型15．9％，XX型的骨密度在腰椎、股骨颈和Ward’s三角要高于Xs型和xx型。但ER多态性与骨密度无相关性。在Xx型和XX型人群中年龄越大，绝经年限越长，腰椎和股骨上端骨密度则越低。在XX型中，BMI是影响股骨颈和Ward’s三角骨密度的主要因素。而在xx型中，腰椎和ward’s三角骨密度与年龄、BMI和绝经年限无相关性，绝经年限与股骨颈骨密度相关，大转子与BMI相关。结论 福州地区绝经后骨质疏松人群ER基因XbaⅠ基因型与骨密度无明显相关性，但在不同基因型人群中，其骨密度的丢失趋势和影响因素也各异，临床上应采用不同的防治措施。     

腰椎间盘突出对绝经后妇女骨密度的影响分析

目的探讨腰椎间盘突出对绝经后妇女骨密度的影响。方法随机选择绝经后妇女进行问卷调查,内容包括身高、体重、是否有腰椎间盘突出、生活习惯、健康状况等;用双能X线骨密度仪测定腰椎、髋部骨密度,并利用SPSS 20.0统计软件对数据进行分析。结果共筛选入组582例,腰椎间盘突出组133例、腰椎间盘无突出组449例。对各因素与骨质疏松的相关性分析,腰椎间盘突出与腰椎椎体骨密度具有负相关(r=-0.094,P=0.023);两组一般资料比较,日光照射、腰椎骨密度差异比较有统计学意义(P0.05);协方差分析,腰椎间盘无突出组腰椎骨密度(0.734±0.123)g/cm~2明显高于腰椎间盘突出组腰椎骨密度(0.707±0.123)g/cm~2,差异有统计学意义(F=3.968,P=0.047),髋部骨密度差异无统计学意义(P0.05);两组骨质疏松患病率比较,腰椎间盘突出组为55.6%,腰椎间盘无突出组为43.7%,两组比较差异有统计学意义(P=0.015)。结论腰椎间盘突出能够引起腰椎骨量流失,是引起骨质疏松发生的影响因素。     

绝经后女性骨质疏松性椎体骨折与腰椎体骨密度的相关性

随着我国步入老龄化社会,骨质疏松症的患病率明显升高。骨质疏松症最严重的危害来自骨质疏松性骨折,绝经后女性尤其多见。由于脊柱独特的解剖学和生物力学特点,骨质疏松患者更易发生椎体骨折。骨密度测量是诊断骨质疏松的金标准。本文通过回顾近年来相关文献,探讨腰椎体骨密度检测对绝经后女性骨质疏松性椎体骨折的意义,发现:绝经后骨质疏松性椎体骨折患者的BMD水平比绝经后骨质疏松症但无脊椎骨折者明显减少;绝经后骨质疏松症患者的BMD水平越低,其发生椎体骨折的风险越高;有椎体骨折史的绝经后骨质疏松症患者的BMD水平与发生再次椎体骨折的风险呈负相关。药物干预通常可明显提高绝经后骨质疏松症患者的BMD水平,同时还可减少椎体骨折的发生。尚存在一些不足:腰椎骨密度可能出现假性增高;需进一步探讨预测骨质疏松性椎体骨折的骨密度阈值;药物干预的研究中BMD水平与椎体骨折发生的相关性并没有得到深入研究;缺少大规模的绝经后骨质疏松性椎体骨折的流行病学,现有研究也大都存在病例收集方法不规范、样本量小、年龄分布存在差异等不足。对绝经后骨质疏松性椎体骨折的深入研究需要多学科共同协作。     

颈动脉内膜中层厚度和绝经后妇女骨密度相关性研究

目的探讨绝经后骨质疏松症患者颈动脉内膜中层厚度(CIMT)的差异及CIMT和斑块增大的风险。方法进行横断面研究,包括60位绝经后骨质疏松症妇女和60位非骨质疏松症绝经后妇女。CIMT采用B型超声测量。结果绝经后骨质疏松症妇女与无骨质疏松症妇女的平均CIMT差异无统计学意义(P 0.05)。骨质疏松症组CIMT升高的风险与非骨质疏松症组相似。骨质疏松症妇女斑块出现的风险是正常人的三倍。然而,调整了易使妇女患有心血管疾病的年龄和基础疾病后,两组之间斑块的存在并无显着差异(校正比值比=0.85;95%可信区间0.10～6.464)。结论绝经后妇女与无骨质疏松症患者的平均CIMT无差异。绝经后骨质疏松症女性的CIMT升高风险与无骨质疏松症的绝经后妇女相当。两组之间斑块的存在没有显着差异。     

绝经后骨质疏松及骨量减少患者治疗前后骨密度变化的研究

目的 观察利塞膦酸钠防治绝经后骨质疏松症的疗效。方法 绝经后骨质疏松症48例,对照组24例,服安慰剂,实验组24例,服利塞膦酸钠5 mg/d,两组每日均服凯思立D 1片,2组共观察6月。结果 利塞膦酸钠组腰椎、股骨颈及大粗隆的骨密度均明显升高(P<0.05),实验组总有效率为80.95％,明显高于对照组的45.45％(P<0.01)。结论 利塞膦酸钠能明显提高绝经后骨质疏松症患者的骨密度,副作用轻。     

Relations between calcidiol serum levels and bone mineral density in postmenopausal women with low bone density

The relationship between vitamin D and bone density was studied in 150 selected, mature (45–74), postmenopausal women with a lumbar spine Z score below 0. Vitamin D status was evaluated using calcidiol serum levels. Serum calcitriol and parathyroid hormone (PTH) values were also evaluated in some subjects. Bone mass was evaluated by ascertaining bone density and Z and T scores in the lumbar spine and femur region. The reference group consisted of 25 premenopausal women. The postmenopausal group was divided into subgroups according to age, i.e., under or over 60 years old. Additionally, the whole group was also subdivided according to their lumbar spine Z scores into group I (Z>-1), group II (Z<-1; >-2), and group III (Z<-2). Group III of postmenopausal women had higher PTH and lower calcitriol levels than premenopausal women. Calcidiol serum levels were lower in postmenopausal women groups II or III than in the group I and premenopausal women. Calcidiol serum levels and the bone mass values for the lumbar spine were correlated positively in all the postmenopausal women; in the women over 60 years of age, calcidiol levels also correlated with the bone mass values expressed as the bone density in three femur regions: femoral neck, trocanter, and Ward's triangle. In conclusion, mature postmenopausal woman showed high PTH levels and low calcidiol and calcitriol values. Calcidiol status is significantly related to bone mineral density in the lumbar spine and in women over 60 years, calcidiol levels also correlated with bone density in the femur regions.